UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

JQ Wu, JF Seymour, B Eichhorst, P Hillmen, T Kipps, AW Langerak, C Owen, J Dubois, C Mellink, A van der Kevie‐Kersemaekers, B Chyla, Y Jiang, M Boyer, M Thadani‐Mulero, M Lefebure, AP Kater